Week in Medicine News and Research RSS Feed - Week in Medicine News and Research

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

EGFR–TKIs linked to reduced chemotherapy sensitivity in NSCLC

Epidermal growth factor receptor–tyrosine kinase inhibitors appear to significantly reduce the efficacy of subsequent chemotherapy in patients with EGFR-mutated non-small-cell lung cancer, Chinese researchers report. [More]
Inappropriate lung cancer imaging widespread in USA

Inappropriate lung cancer imaging widespread in USA

A large proportion of patients with lung cancer do not receive guideline-recommended imaging, US study data show. [More]
Endemic lung infection compromises lung cancer diagnosis

Endemic lung infection compromises lung cancer diagnosis

The accuracy of lung cancer diagnosis using 18F-fluorodeoxyglucose–positron emission tomography may be compromised in areas with endemic infectious lung diseases, research suggests. [More]
Adjuvant cisplatin for NSCLC raises non-cancer mortality risk

Adjuvant cisplatin for NSCLC raises non-cancer mortality risk

Re-analysis of data from the International Adjuvant Lung Cancer Trial indicates that cisplatin-based adjuvant chemotherapy increases the long-term risk of non-cancer mortality in patients with non-small-cell lung cancer. [More]
Intrathoracic radiotherapy shows potential in extensive-stage SCLC

Intrathoracic radiotherapy shows potential in extensive-stage SCLC

A phase III randomised controlled trial shows that intrathoracic radiotherapy after chemotherapy significantly reduces the chances of disease progression in patients with extensive-stage small-cell lung cancer. [More]
Afatinib active against NSCLC nervous system metastases

Afatinib active against NSCLC nervous system metastases

Heavily pretreated patients with epidermal growth factor receptor-mutated non-small-cell lung cancer and central nervous system metastases may benefit from treatment with afatinib, say German researchers. [More]
Six platinum cycles no better than four for advanced NSCLC

Six platinum cycles no better than four for advanced NSCLC

Six cycles of adjuvant platinum-based chemotherapy is no better than three or four cycles for patients with advanced non-small-cell lung cancer, meta-analysis results suggests. [More]

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

A review of patients with advanced pulmonary carcinoid tumours shows that they can be responsive to chemotherapy. [More]

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show. [More]
XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

XAGE1 antibody confers survival benefits to lung adenocarcinoma patients

Patients with advanced lung adenocarcinoma who produce the XAGE1 antibody appear to survive twice as long as those who do not produce it, Japanese study data show. [More]
Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report. [More]
Ramucirumab effective second-line option for NSCLC

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial. [More]
Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest. [More]
S-1 plus radiotherapy shows promise in elderly NSCLC patients

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Concurrent administration of S-1 chemotherapy and radiotherapy has a favourable impact on survival in elderly patients with locally advanced non-small-cell lung cancer, a phase II trial has found. [More]
Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and anatomic segmentectomy appear to offer similar perioperative and oncological outcomes in patients with stage I non-small-cell lung cancer, analysis suggests. [More]
Vaccine boosts advanced NSCLC patient survival

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy. [More]
Mutant allele frequency predicts lung cancer TKI response

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma. [More]
Stereotactic radiosurgery feasible for multiple brain metastases

Stereotactic radiosurgery feasible for multiple brain metastases

Stereotactic radiosurgery is a feasible treatment option for cancer patients with up to 10 brain metastases, Japanese researchers report in The Lancet Oncology. [More]
High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report. [More]
Preoperative ultrasound reveals NSCLC chest wall invasion

Preoperative ultrasound reveals NSCLC chest wall invasion

Surgeon-performed ultrasound is a good alternative to computed tomography for the identification of chest wall invasion in patients with non-small-cell lung cancer, suggests research demonstrating 90% sensitivity for detection of the spread. [More]